Viking Therapeutics (NASDAQ:VKTX) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(1.02) by 34.31 percent. This is a 234.15 percent decrease over losses of $(0.41) per share from the same period last year.